Clinical Research Directory
Browse clinical research sites, groups, and studies.
Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
Sponsor: Children's Hospital Medical Center, Cincinnati
Summary
The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
Official title: A Pilot Study to Evaluate Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
Key Details
Gender
MALE
Age Range
2 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-02-26
Completion Date
2029-06
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
Quercetin
Quercetin will be administered orally at a weight adjusted dose for a maximum total daily dose of 4000mg/day, divided twice a day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day. Patients will be instructed to mix quercetin with a small amount of yogurt or other preferred food for ingestion.
Locations (1)
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States